Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

BACKGROUND: Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are common in acute myeloid leukemia (AML) and are associated with rapid relapse and short survival. In relapsed/refractory (R/R) AML, the clinical benefit of FLT3 inhibitors has been limited by rapid generation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Perl, Alexander E., Altman, Jessica K., Cortes, Jorge, Smith, Catherine, Litzow, Mark, Baer, Maria R., Claxton, David, Erba, Harry P., Gill, Stan, Goldberg, Stuart, Jurcic, Joseph G., Larson, Richard A., Liu, Chaofeng, Ritchie, Ellen, Schiller, Gary, Spira, Alexander I., Strickland, Stephen A., Tibes, Raoul, Ustun, Celalettin, Wang, Eunice S., Stuart, Robert, Röllig, Christoph, Neubauer, Andreas, Martinelli, Giovanni, Bahceci, Erkut, Levis, Mark
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572576/
https://ncbi.nlm.nih.gov/pubmed/28645776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30416-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky